General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Fixed-income securities information

CHF fixed-income securities

Issuer Amount
(in millions)
Coupon Maturity
Novartis AG 800 3.625% 2015

Credit ratings of Novartis AG

Moody's Standard & Poor's Fitch
Short term P-1 A-1+ F1+
Long term Aa3 AA- AA
Outlook Stable Stable Stable

Novartis AG

Principal amount CHF 800,000,000
ISIN CH0043089009
Issuer Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.625%
Coupon payment date June 26
Documentation Swiss stand-alone documentation
First settlement date June 26, 2008
Issue price 100.3500
Maturity date June 26, 2015
Joint book-runners Credit Suisse, UBS
Bloomberg NOVNVX 3.625 06/26/15
Listing SIX Swiss Exchange

The information provided on this website does not constitute investment advice, or an offer of, or an invitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice whether governing law permits the use or possession of the information provided.

Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information or other documentation related to the securities described above and below.

Stock chart